The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was Bedømmelse af resistens mod lopinavir hos patienter, hvor tidligere behandling med protease - hæmmere var mislykkedes, var karakteriseret ved analyse af isolater fra længderetningen fra 19 protease hæmmer- erfarne forsøgspersoner i 2 fase II - og et fase III- forsøg, som enten oplevede ufuldstændig virologisk undertrykkelse eller viral rebound efter initial respons på Kaletra, og som udviste trinvis voksende in- vitro- resistens mellem baseline og rebound (defineret som tilsynekomst af nye mutationer eller 2- gange ændring i fænotype- følsomhed for lopinavir).
The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was characterised by analysing the longitudinal isolates from 19 protease inhibitor-experienced subjects in 2 Phase II and one Phase III studies who either experienced incomplete virologic suppression or viral rebound subsequent to initial response to Kaletra and who demonstrated incremental in vitro resistance between baseline and rebound (defined as emergence of new mutations or 2-fold change in phenotypic susceptibility to lopinavir).